Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

991.15 +3.88 (+0.39%)
Streaming Delayed Price Updated: 12:41 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Esperion Chops 40% Workforce As Launch Of Cholesterol Medication Falters
Esperion Therapeutics Inc's (NASDAQ: ESPR) cholesterol drug marketing strategy has soured badly, as it has been struggling to sell its heart disease pill for more than a... 
Via Benzinga
Vaccine Makers Slump As Oral Antivirals Begin To Take Center Stage
Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral... 
Via Talk Markets
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news.... 
Via Benzinga
Exposures Product Safety
3 No-Brainer Biotech Stocks to Buy Right Now
Regeneron Pharmaceuticals, Vertex Pharmaceuticals, and Viatris should have plenty of room to run. 
Via The Motley Fool
The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies
Companies working on sorely needed Covid treatments are innovating to keep up. 
Via Investor's Business Daily
2 Cheap Growth Stocks That Could Be Even Better Buys in November
Both of these companies are reporting earnings within the next month, and there could be a dip in price that follows. 
Via The Motley Fool
Why Regeneron Shares Are Rising Today
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is trading higher Thursday after the company announced the FDA accepted for priority review a Biologics License Application for... 
Via Benzinga
Exposures Product Safety
Expert Ratings For Regeneron Pharmaceuticals
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has obser... 
Via Benzinga
AstraZeneca's COVID-19 Therapy Hits Goal In Phase 3 Trial
AstraZeneca Plc (NASDAQ: AZN) released top-line data from the TACKLE Phase 3 trial in which its experimental COVID-19 drug has helped cut the risk of severe disease... 
Via Benzinga
Exposures COVID-19
Regeneron Could Have a Big Catalyst Coming in 2022
Cancer drug Libtayo could receive FDA approval for its fourth indication in January. 
Via The Motley Fool
Exposures Product Safety
Cramer Likes DraftKings, Skyworks, And These Automakers
On CNBC's "Mad Money Lightning Rou... 
Via Benzinga
Tesla and Merck Give Investors Some Hope
Friday’s rally appears to have lost its momentum over the weekend because stock futures are trading lower before Monday’s open. China’s troubled real estate... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
Why Moderna, Novavax And Other COVID-19 Vaccine Stocks Are Plummeting
The COVID-19 pandemic proved to be a boon for many biopharma companies that benefited from their foray into the development of vaccines and/or treatments against the novel... 
Via Benzinga
Exposures COVID-19
Merck Stock Surges Into Buy Zone As Covid Pill Reduces Risk Of Death, Hospitalization
Merck said its Covid pill, molnupiravir, cut the risk of death and hospitalization by half. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Regeneron-Roche Post Encouraging New Data For COVID-19 Antibody Cocktail
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holdings AG (OTC: RHHBY) announced positive data from Phase 2/3 2066 study of Ronapreve (... 
Via Benzinga
Exposures COVID-19
Graybug Vision Posts Six-Month Extension GB-102 Data Of Wet AMD Trial
Graybug Vision Inc (NASDAQ: GRAY) has provided a full-data analysis from the 18-month Phase 2b ALTISSIMO trial of GB-102 for wet age-related macular degeneration (wet AMD).... 
Via Benzinga
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
Via Benzinga
Glaxo - Vir Biotech's COVID Treatment Approved In Japan
Japan's health ministry expert committee has approved GlaxoSmithKline Plc (NYSE: GSK) - Vir Biotechnology Inc's (NASDAQ: VIR) sotrovimab, a COVID-19... 
Via Benzinga
WHO Backs Regeneron COVID-19 Antibody Cocktail As It Calls For Equal Access
The World Health Organization (WHO) has supported another COVID-19 therapeutic but urged the related companies and governments to address the high price and limited... 
Via Benzinga
Exposures COVID-19
Ligand Pharmaceuticals Stock Shows Rising Price Performance
A Relative Strength Rating upgrade for San Diego-based Ligand Pharmaceuticals stock shows improving technical performance. 
Via Investor's Business Daily
Acceleron Pharma Stock Meets 80-Plus Relative Strength Rating Benchmark
Want to build a watch list? Focus on stocks with an 80-plus RS Rating. Acceleron Pharma stock cleared that benchmark with an upgrade to 83. 
Via Investor's Business Daily
Inmune Bio Stock Flashes Robust RS Rating
On Wednesday, Inmune Bio stock saw its Relative Strength Rating jump into the 90-plus percentile, to 92 from 85 the day before. 
Via Investor's Business Daily
Where to Invest $100 Right Now
These choices may surprise you. 
Via The Motley Fool
3 COVID Stocks to Buy in a Bear Market
If COVID-19 shocks the market again, our trio of Fools suggest that you might want to own shares of Moderna, Regeneron, and Figs. 
Via The Motley Fool
Exposures COVID-19
I-Mab Stock Joins Rank Of Stocks With RS Ratings Over 90
Looking for the best stocks to buy? Focus on those with rising relative strength such as I-Mab stock, which saw a (RS) Rating upgrade to 93. 
Via Investor's Business Daily
Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) hope to expand Libtayo into a broader population with a chemo combo regimen. ... 
Via Benzinga
AbbVie's Pain Is Sanofi's and Regeneron's Gain
There are both winners and losers with the new Food and Drug Administration restrictions on JAK inhibitors. 
Via The Motley Fool
Exposures Product Safety
Look For The Q4 Biotech Bounce In Mid-Small Caps
Large-cap biopharma stocks are off their highs because of prospects that drug prices may be directly negotiated through Medicare but several Democrats are not in agreement as to how this could be best... 
Via Talk Markets
Analyst Ratings For Regeneron Pharmaceuticals
Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ... 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.